Incanthera PLC (AQSE: INC) has secured its second production order for 250,000 units from Marionnaud AG, a subsidiary of the Watsons Group.
Specializing in innovative dermatological technologies, Incanthera noted that this follows an earlier increase in its initial production order from 50,000 to 100,000 units, projected to generate around £4 million in revenue.
The new order is intended to address the expected demand in both European and Asian markets.
This development means Incanthera now expects its revenues for the current financial year to exceed £10 million, positioning the company towards achieving profitability.
Commenting, Chairman, Tim McCarthy, said: “It is fantastic to bring this further positive update to the market.
This clearly evidences the confidence and anticipation with which Incanthera, and its Swiss subsidiary, Skin + CELL A.G. is managing the production order cycle, in close coordination with Marionnaud, as the teams work collaboratively towards the launch and rollout of Skin + CELL in Europe.
The essential infrastructure and framework that the team established for the Commercial deal announcement in December 2023 is now in full operation as we ramp up the production orders and prepare for launch.
The resulting revenues generated to Incanthera will allow us to further bolster our inventory capacity and ongoing commercial operational model, thereby driving revenue growth and, in turn, increasing the value of our company and the capacity for returns to shareholders.”
